Tuesday tips round-up: BTG, Witan Pacific, Greene King

24th Apr 2012 06:59

Questor in the Telegraph likes biotech firm BTG which has had positive results in tests for what could the first non-surgical treatment for varicose veins. With interests in anti-venom agents for the treatment of viper bites, the firm has an interesting portfolio and merits a hold from Questor for future growth.Tempus in the Times thinks Witan Pacific Investment Trust has acted ruthlessly in sacking one of its fund managers, Nomura. New mandates have been given to the US firm Matthews International and to the Hong Kong-based Marshall Wace GaveKal, with Aberdeen Asset Management retained. The net effect will be "ballsier" bets says Tempus, with more manoeuvrability in the face of an equities slump and less exposure to Japan. Witan Pacific still trades at an 18% discount to net assets and in the view of Tempus, the board deserves the benefit of the doubt over its decision to ditch Nomura, but shareholders should keep an eye out for further falls.Tempus is warmer on pub company Greene King, which has been boosted by increases in like-for-like (LFL) sales, particularly in food. The Hungry Horse budget offering is the fastest growing unit, while the Chief Exec Rooney Anand is interested in growing the property portfolio, although perhaps not in acquiring Mitchells and Butlers. Any company delivering LFL increases deserves some credit, Greene King is a "strong hold".Please note: Digital Look provides a round-up of news, tips and information that is impacting share prices and the market. Digital Look cannot take any responsibility for information provided by third parties. This is for your general information only as not intended to be relied upon by users in making an investment decision or any other decision. Please obtain a copy of the relevant publication and carry out your own research before considering acting on any of this information.BS